Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 1 to 20 of 570

1.

Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ.

J Urol. 2011 Mar;185(3):869-75. doi: 10.1016/j.juro.2010.10.057. Epub 2011 Jan 15.

2.

Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.

Hernandez DJ, Nielsen ME, Han M, Trock BJ, Partin AW, Walsh PC, Epstein JI.

Urology. 2008 Jul;72(1):172-6. doi: 10.1016/j.urology.2007.10.055. Epub 2008 Mar 4.

3.

Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer.

Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC.

J Urol. 2001 Aug;166(2):416-9.

PMID:
11458039
4.

Causes of death after radical prostatectomy at a large tertiary center.

Eifler JB, Humphreys EB, Agro M, Partin AW, Trock BJ, Han M.

J Urol. 2012 Sep;188(3):798-801. doi: 10.1016/j.juro.2012.04.109. Epub 2012 Jul 20.

PMID:
22819416
6.

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.

Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.

J Urol. 2003 Feb;169(2):517-23.

PMID:
12544300
7.

The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.

Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M.

Eur Urol. 2015 Feb;67(2):342-6. doi: 10.1016/j.eururo.2014.06.015. Epub 2014 Jun 23.

PMID:
24968968
8.
9.

Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy.

Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML.

J Urol. 2008 May;179(5):1780-4; discussion 1784. doi: 10.1016/j.juro.2008.01.032. Epub 2008 Mar 17.

10.
11.
12.

Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.

Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, Montie JE, Pearson JD, Slezak JM, Zincke H.

J Urol. 2000 Nov;164(5):1591-5.

PMID:
11025711
13.

Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.

Khan MA, Han M, Partin AW, Epstein JI, Walsh PC.

Urology. 2003 Jul;62(1):86-91; discussion 91-2.

PMID:
12837428
14.

Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center.

Nielsen ME, Han M, Mangold L, Humphreys E, Walsh PC, Partin AW, Freedland SJ.

J Urol. 2006 Aug;176(2):515-9.

PMID:
16813880
15.
16.

Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching.

Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML.

Urology. 2008 Dec;72(6):1246-51. doi: 10.1016/j.urology.2008.01.052. Epub 2008 Apr 2.

17.

Radical prostatectomy for high grade disease: a reevaluation 1994.

Partin AW, Lee BR, Carmichael M, Walsh PC, Epstein JI.

J Urol. 1994 Jun;151(6):1583-6.

PMID:
8189569
18.

Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer.

Han M, Piantadosi S, Zahurak ML, Sokoll LJ, Chan DW, Epstein JI, Walsh PC, Partin AW.

Urology. 2001 Apr;57(4):707-11.

PMID:
11306387
19.
20.

Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.

Chan TY, Partin AW, Walsh PC, Epstein JI.

Urology. 2000 Nov 1;56(5):823-7.

PMID:
11068310

Supplemental Content

Support Center